Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | RAD52 | P43351 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | SYK | P43405 | 2/20 | 0.57 |
| ▸ | ACP1 | P24666 | 3/20 | 0.55 |
| ▸ | NCF1 | P14598 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23029630 | 1.00 | SLC2A1 (0.61) | SLC2A1POLBRAD52KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL29636808 | 0.99 | SLC2A1 (0.60) | SLC2A1POLBRAD52KDM4EALDH1A1 | |
| SCHEMBL16123741 | 0.88 | SLC2A1 (0.68) | SLC2A1POLBRAD52KDM4EALDH1A1 | |
| SCHEMBL23029631 | 0.87 | SLC2A1 (0.55) | SLC2A1POLBRAD52KDM4EALDH1A1 | |
| SCHEMBL23029627 | 0.86 | SYK (0.57) | SLC2A1SYK | |
| SCHEMBL30261191 | 0.86 | SYK (0.57) | SLC2A1SYK | |
| SCHEMBL16123717 | 0.84 | SLC2A1 (0.85) | SLC2A1POLBRAD52KDM4EALDH1A1 | |
| SCHEMBL6751104 | 0.81 | SLC2A1 (0.61) | SLC2A1POLBRAD52KDM4EALDH1A1 | |
| SCHEMBL16123691 | 0.81 | SLC2A1 (0.79) | SLC2A1POLBRAD52KDM4EALDH1A1 | |
| SCHEMBL23029601 | 0.81 | SLC2A1 (0.70) | SLC2A1POLBRAD52KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 2022-12-08 | — | — | US | claimed |
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | FOX CHASE CHEMICAL DIVERSITY CENTER INC. | 2022-12-08 | — | — | US | disclosed |
| EP-4017492-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | Biohaven Therapeutics Ltd. (US) | 2022-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388962-A1 | MOLECULES THAT BIND TO TDP-43 FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS | TARDBP, TDP1, TDP2 | SLC2A1 2706/4885POLB 994/4885RAD52 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.